Newsroom - Alvotech - Better Access Better Lives

Skip Navigation

Alvotech

Latest news

21 February 2025

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

18 February 2025

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

27 January 2025

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Media Contact

Benedikt Stefansson

Director of Investor Relations and Global Communications

Phone +354 422 4500

Connect on Linkedin

Media Gallery

Download center for company logos and images

Alvotech 2022. All rights reserved.